Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: A pilot study

Pain Medicine

Volumn 9, Issue 8, 2008, Pages 1209-1216

  Tsavaris, Nicolas ^a   Kopterides, Petros ^a,d   Kosmas, Christos ^b   Efthymiou, Athina ^a   Skopelitis, Hlias ^a   Dimitrakopoulos, Antonios ^a   Pagouni, Eyterpi ^a   Pikazis, Dimitrios ^a   Zis, Panagiotis Vasilis ^c   Koufos, Christos ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d NONE   (Greece)

Author keywords

Chemotherapy; Gabapentin; Neuropathic pain; Neuropathy; Neurotoxicity; Palliative care

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; COCODAMOL; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GABAPENTIN; GEMCITABINE; IFOSFAMIDE; NAPROXEN; NAVELBINE; OXALIPLATIN; PACLITAXEL;

ADULT; AGED; ANALGESIA; ARTICLE; BEDTIME DOSAGE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GERM CELL TUMOR; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUROPATHIC PAIN; NEUROTOXICITY; OVARY CANCER; PILOT STUDY; SARCOMA; SOMNOLENCE;

ADULT; AGED; AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; NEURALGIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56849094393     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2007.00325.x     Document Type: Article

References (32)

1. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 1999;82(3):263-74.
2. Chen H, Lamer TJ, Rho RH, et al. Contemporary management of neuropathic pain for the primary care physician. Mayo Clin Proc 2004;79(12):1533-45.
3. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: Pathogenesis and emerging therapies. Support Care Cancer 2004;12(9):619-25.
4. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9-17.
5. Plotkin SR, Wen PY. Neurologic complications of cancer therapy. Neurol Clin 2003;21(1):279-318.
6. McMahon S, Priestley J. Peripheral neuropathies and neurotrophic factors: Animal models and clinical perspectives. Curr Opin Neurobiol 1995;5(5):616-24.
7. Partridge BJ, Chaplan SR, Sakamoto E, Yaksh TL. Characterization of the effects of Gabapentin and 3-isobutyl-gamma-aminobutyric acid on substance P-induced thermal hyperalgesia. Anesthesiology 1988;88(1):196-205.
8. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. A double blind randomized controlled trial. JAMA 1998;280(21):1837-42.
9. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: A randomised, double blind, placebo-controlled study. Pain 2001;94(2):215-24.
10. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA 1998;280(21):1831-6.
11. Hahn K, Arendt G, Braun JS, et al. German Neuro-AIDS Working Group. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004;251(10):1260-6.
12. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom-limb pain: A randomized, double-blind, placebo-controlled cross-over study. Reg Anesth Pain Med 2002;27(5):481-6.
13. Caraceni A, Zecca E, Martini C, De Conno F. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 1999;17(6):441-5.
14. Chandler A, Williams JE. Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital. J Pain Symptom Manage 2000;20(2):82-6.
15. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 1994;35(3):304-11.
16. Hayakawa K, Itoh T, Niwa H, Mutoh T, Sobue G. NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: In vitro study of adult rat sympathetic ganglion explants. Brain Res 1998;794(2):313-9.
17. Contreras PC, Vaught JL, Gruner JA, et al. Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res 1997;774(1-2):20-6.
18. Gelmon K, Eisenhauer E, Bryce C, et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 1999;17(10):3038-47.
19. De Vos FY, Bos AM, Schaapveld M, et al. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 2005;97(1):60-7.
20. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002;20(16):3478-83.
21. Parnis FX, Coleman RE, Harper PG, et al. A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 1995;31A(10):1721.
22. Pronk LC, Hilkens PH, van den Bent MJ, van Putten WL, Stoter G, Verweij J. Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 1998;9(9):759-64.
23. van der Hoop RG, Vecht CJ, van der Burg ME, et al. Prevention of cisplatin neurotoxicity with an ACTH (4-9) analogue in patients with ovarian cancer. N Engl J Med 1990;322(2):89-94.
24. Cassidy J, Paul J, Soukop M, et al. Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharmacol 1998;41(2):161-6.
25. Jacobson SD, Loprinzi CL, Sloan JA, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 2003;1(4):274-8.
26. Durand JP, Alexandre JR, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005;16(5):587-91.
27. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: A randomized placebo-controlled, double-blind crossover study. Tumori 2002;88(3):239-42.
28. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2-delta subunit of a calcium channel. J Biol Chem 1996;271(10):5768-76.
29. Luo ZD, Chaplan SR, Higuera ES, et al. Upregulation of dorsal root ganglion (alpha) 2-(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 2001;21(6):1868-75.
30. Oneschuk D, al-Shahri MZ. The pattern of gabapentin use in a tertiary palliative care unit. J Palliat Care 2003;19(3):185-7.
31. Caraceni A, Zecca E, Bonezzi C, et al. Gabapentin for neuropathic cancer pain: A randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 2004;22(14):2909-17.
32. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998;9(7):739-44.